Video
Author(s):
Yousef Zakharia, MD, discusses the design and results of a phase 2 trial that explored concurrent treatment with radiation and the PD-L1 inhibitor durvalumab (Imfinzi) followed by adjuvant durvalumab in patients with urothelial cancer. Zakharia is clinical associate professor of internal medicine at the University of Iowa, Holden Comprehensive Cancer Center.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.